ESTRO 2022 - Abstract Book

S1187

Abstract book

ESTRO 2022

Conclusion Online adaptive MR-Guided SBRT of prostate cancer using daily re-optimization resulted in better target coverage as compared with non-adaptive SBRT, this was especially true for the GTV where the non-adaptive coverage ranged from 55%- 97%. Generally, the OARs fared well in the non-adaptive setting with moderately increased sparing for adaptive fractions.

PO-1400 Safety and feasibility of PSMA-PET guided SBRT to Oligo-Metastatic Prostate Cancer

A. Gawish 1 , H. Ochel 1 , T.B. Brunner 1

1 Medical Faculty University Hospital Magdeburg, University Clinic for Radiation Therapy, Magdeburg, Germany